Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec)
## Overview
Durveqtix is an adeno-associated virus vector-based gene therapy designed to deliver a functional copy of the human coagulation factor IX (FIX) gene to hepatocytes. It is a one-time infusion intended to provide long-term endogenous production of Factor IX in patients with hemophilia B.
## Primary Indications
Treatment of adults (18 years or older) with moderately severe to severe hemophilia B (congenital Factor IX deficiency) who are currently using Factor IX prophylactic therapy or have a current or historical life-threatening hemorrhage or repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is 5 x 10^11 vector genomes per kilogram (vg/kg) of body weight, administered as a single intravenous infusion.
## Pediatric Dosing
Safety and efficacy in pediatric patients (younger than 18 years) have not been established. Use in this population is not recommended.
## Dose Adjustments
There are no dose adjustments for the gene therapy itself. However, patients must be managed with a tapering course of prophylactic corticosteroids (e.g., prednisone 60 mg/day or equivalent) starting shortly after infusion to mitigate liver enzyme elevations associated with immune responses to the vector.
## Contraindications
The product is contraindicated in patients with known hypersensitivity to the active substance or any excipients.
## Adverse Effects
* **Common:** Increase in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), nausea, headache, injection-site reactions, and fatigue.
* **Serious:** Potential for hepatotoxicity due to immune-mediated clearance of transduced cells; risk of infusion-related reactions (fever, chills, hypotension).
* **Hypothetical:** Long-term risk of malignancy due to vector integration (currently low, but requires surveillance).
## Key Drug Interactions
There are no established pharmacological interactions with chronic medications. However, avoid medications that may exacerbate hepatotoxicity (e.g., high-dose acetaminophen) during the post-infusion monitoring period.
## Monitoring
* **Liver Enzymes:** Monitor ALT/AST levels weekly for at least the first 12–16 weeks post-infusion.
* **Factor IX Activity:** Monitor plasma Factor IX activity levels periodically to ensure therapeutic expression and durability.
* **Coagulation:** Monitor for bleeding events, especially during the transition period from prophylaxis to endogenous expression.
## Clinical Pearls
* **Corticosteroid Taper:** A liver-directed immunosuppressive regimen (corticosteroids) is mandatory to prevent or treat potential immune-mediated liver injury, which can lead to the loss of therapeutic expression if not managed quickly.
* **Pre-screening:** Patients must be screened for pre-existing anti-AAV vector antibodies; those with high titers may not be eligible candidates as neutralizing antibodies can render the therapy ineffective.
* **One-Time Therapy:** This is a definitive treatment. Patients should be counseled that the long-term duration of effect beyond the current clinical trial data remains an area of ongoing study.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Prescribing information, including black box warnings and regional regulatory status, is subject to change. Always verify the current package insert, institutional protocols, and local regulatory guidance before prescribing or administering this therapy.
